0001376339false00013763392020-10-302020-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

____________________

FORM 8-K

____________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 30, 2020

MIMEDX GROUP, INC.

(Exact name of registrant as specified in charter)

Florida

001-35887

26-2792552

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

1775 West Oak Commons Ct., NE, Marietta GA 30062

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (770) 651-9100

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

None

n/a

n/a

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

Item 7.01 Regulation FD Disclosure.

On October 30, 2020, MiMedx Group Inc., (the "Company")issued a press release announcing that The Nasdaq Stock Market LLC approved its application for listing the Company's common stock on the Nasdaq Stock Market. A copy of the press release is attached hereto as exhibit 99.1 and is incorporated herein by reference.

It is expected that the Company's common stock will begin trading on the Nasdaq Stock Market at the opening of trading on or before November 5, 2020 under the symbol "MDXG".

Also on October 30, 2020, Timothy R. Wright, Chief Executive Officer of the Company published a letter to shareholders which discusses the Company's relisting on Nasdaq, having distributed its 2 millionth allograft, and future Company objectives. A copy of the letter to shareholders is attached hereto as Exhibit 99.2 and is incorporated herein for reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description of Exhibit
99.1						Press Release dated October 30, 2020
99.2						Letter to Shareholders dated October 30, 2020
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						MIMEDX GROUP, INC.
Date: October 30, 2020			By:			/s/ Peter M. Carlson
						Peter M. Carlson Chief Financial Officer

---